BACKGROUND AND METHODS. The use of corticosteroids to treat optic neuritis is controversial. At 15 clinical centers, we randomly assigned 457 patients with acute optic neuritis to receive oral prednisone (1 mg per kilogram of body weight per day) for 14 days; intravenous methylprednisolone (1 g per day) for 3 days, followed by oral prednisone (1 mg per kilogram per day) for 11 days; or oral placebo for 14 days. Visual function was assessed over a six-month follow-up period. RESULTS. Visual function recovered faster in the group receiving intravenous methylprednisolone than in the placebo group; this was particularly true for the reversal of visual-field defects (P = 0.0001). Although the differences between the groups decreased with time, at six months the group that received intravenous methylprednisolone still had slightly better visual fields (P = 0.054), contrast sensitivity (P = 0.026), and color vision (P = 0.033) but not better visual acuity (P = 0.66). The outcome in the oral-prednisone group did not differ from that in the placebo group. In addition, the rate of new episodes of optic neuritis in either eye was higher in the group receiving oral prednisone, but not the group receiving intravenous methylprednisolone, than in the placebo group (relative risk for oral prednisone vs. placebo, 1.79; 95 percent confidence interval, 1.08 to 2.95). CONCLUSIONS. Intravenous methylprednisolone followed by oral prednisone speeds the recovery of visual loss due to optic neuritis and results in slightly better vision at six months. Oral prednisone alone, as prescribed in this study, is an ineffective treatment and increases the risk of new episodes of optic neuritis.
Source Information
Department of Ophthalmology, University of South Florida College of Medicine, Tampa 33612.
This article has been cited by other articles:
Cotter, S., Kulp, M., Scheiman, M., Hertle, R., Mitchell, G. L., Rouse, M., for the Convergence Insufficiency Treatment Trial,
(2009). Response to Editorial About the Convergence Insufficiency Treatment Trial. Arch Ophthalmol
127: 1229-1230
[Full Text]
OSBORNE, B. J., VOLPE, N. J.
(2009). Optic neuritis and risk of MS: Differential diagnosis and management. Cleveland Clinic Journal of Medicine
76: 181-190
[Abstract][Full Text]
Broadley, S., Vanags, D, Williams, B, Johnson, B, Feeney, D, Griffiths, L, Shakib, S, Brown, G, Coulthard, A, Mullins, P, Kneebone, C
(2009). Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult Scler
15: 329-336
[Abstract]
Mowry, E. M., Pesic, M., Grimes, B., Deen, S., Bacchetti, P., Waubant, E.
(2009). Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology
72: 602-608
[Abstract][Full Text]
Naismith, R. T., Xu, J., Tutlam, N. T., Snyder, A., Benzinger, T., Shimony, J., Shepherd, J., Trinkaus, K., Cross, A. H., Song, S-K
(2009). Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology
72: 589-594
[Abstract][Full Text]
Deen, S, Bacchetti, P, High, A, Waubant, E
(2008). Predictors of the location of multiple sclerosis relapse. J. Neurol. Neurosurg. Psychiatry
79: 1190-1193
[Abstract][Full Text]
Beck, R. W., Gal, R. L.
(2008). Treatment of Acute Optic Neuritis: A Summary of Findings From the Optic Neuritis Treatment Trial. Arch Ophthalmol
126: 994-995
[Full Text]
Volpe, N. J.
(2008). The Optic Neuritis Treatment Trial: A Definitive Answer and Profound Impact With Unexpected Results. Arch Ophthalmol
126: 996-999
[Full Text]
The Optic Neuritis Study Group,
(2008). Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-up. Arch Neurol
65: 727-732
[Abstract][Full Text]
Cohen, J., Calabresi, P., Chakraborty, S., Edwards, K., Eickenhorst, T., Felton, W. III, Fisher, E., Fox, R., Goodman, A., Hara-Cleaver, C., Hutton, G., Imrey, P., Ivancic, D., Mandell, B., Perryman, J., Scott, T., Skaramagas, T., Zhang, H. for the AC
(2008). Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler
14: 370-382
[Abstract]
Qi, X., Sun, L., Lewin, A. S., Hauswirth, W. W., Guy, J.
(2007). Long-term Suppression of Neurodegeneration in Chronic Experimental Optic Neuritis: Antioxidant Gene Therapy. IOVS
48: 5360-5370
[Abstract][Full Text]
Kupersmith, M. J., Gal, R. L., Beck, R. W., Xing, D., Miller, N., The Optic Neuritis Study Group,
(2007). Visual function at baseline and 1 month in acute optic neuritis: Predictors of visual outcome. Neurology
69: 508-514
[Abstract][Full Text]
Shindler, K. S., Ventura, E., Rex, T. S., Elliott, P., Rostami, A.
(2007). SIRT1 Activation Confers Neuroprotection in Experimental Optic Neuritis. IOVS
48: 3602-3609
[Abstract][Full Text]
Balcer, L. J., Galetta, S. L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., for the AFFIRM and SENTINEL Investigators,
(2007). Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology
68: 1299-1304
[Abstract][Full Text]
Choudry, B. A., Chan, J. W.
(2007). An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice
20: 167-180
[Abstract]
Qi, X., Lewin, A. S., Sun, L., Hauswirth, W. W., Guy, J.
(2007). Suppression of Mitochondrial Oxidative Stress Provides Long-term Neuroprotection in Experimental Optic Neuritis. IOVS
48: 681-691
[Abstract][Full Text]
West, T., Wyatt, M., High, A., Bostrom, A., Waubant, E.
(2006). Are initial demyelinating event recovery and time to second event under differential control?. Neurology
67: 809-813
[Abstract][Full Text]
Shindler, K. S, Guan, Y., Ventura, E., Bennett, J., Rostami, A.
(2006). Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult Scler
12: 526-532
[Abstract]
Gold, R., Linington, C., Lassmann, H.
(2006). Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain
129: 1953-1971
[Abstract][Full Text]
Balcer, L. J.
(2006). Clinical practice. Optic neuritis.. NEJM
354: 1273-1280
[Full Text]
Masoud, M. T
(2006). Diagnosis and treatment of multiple sclerosis: Ocular manifestations of multiple sclerosis.. BMJ
332: 668-668
[Full Text]
Sloka, J S, Stefanelli, M
(2005). The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler
11: 425-432
[Abstract]
Schmalfuss, I. M., Dean, C. W., Sistrom, C., Bhatti, M. T.
(2005). Optic Neuropathy Secondary to Cat Scratch Disease: Distinguishing MR Imaging Features from Other Types of Optic Neuropathies. Am. J. Neuroradiol.
26: 1310-1316
[Abstract][Full Text]
Roed, H. G., Langkilde, A., Sellebjerg, F., Lauritzen, M., Bang, P., Morup, A., Frederiksen, J. L.
(2005). A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology
64: 804-810
[Abstract][Full Text]
Optic Neuritis Study Group,
(2004). Long-term Brain Magnetic Resonance Imaging Changes After Optic Neuritis in Patients Without Clinically Definite Multiple Sclerosis. Arch Neurol
61: 1538-1541
[Abstract][Full Text]
Morrow, S. A., Stoian, C. A., Dmitrovic, J., Chan, S. C., Metz, L. M.
(2004). The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology
63: 1079-1080
[Abstract][Full Text]
Optic Neuritis Study Group,
(2004). Neurologic Impairment 10 Years After Optic Neuritis. Arch Neurol
61: 1386-1389
[Abstract][Full Text]
Pirko, I., Blauwet, L. K., Lesnick, T. G., Weinshenker, B. G.
(2004). The Natural History of Recurrent Optic Neuritis. Arch Neurol
61: 1401-1405
[Abstract][Full Text]
Knapp, C M, Constantinescu, C S, Tan, J H., McLean, R, Cherryman, G R, Gottlob, I
(2004). Serum uric acid levels in optic neuritis. Mult Scler
10: 278-280
[Abstract]
Diem, R., Hobom, M., Maier, K., Weissert, R., Storch, M. K., Meyer, R., Bahr, M.
(2003). Methylprednisolone Increases Neuronal Apoptosis during Autoimmune CNS Inflammation by Inhibition of an Endogenous Neuroprotective Pathway. J. Neurosci.
23: 6993-7000
[Abstract][Full Text]
Levin, L. A., Lessell, S.
(2003). Risk of Multiple Sclerosis After Optic Neuritis. JAMA
290: 403-404
[Full Text]
Optic Neuritis Study Group*,
(2003). High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis: Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol
121: 944-949
[Abstract][Full Text]
Levin, L. A., Lessell, S.
(2003). Optic Neuritis and Multiple Sclerosis. Arch Ophthalmol
121: 1039-1040
[Full Text]
Lai, T Y Y, Wong, V W Y, Leung, G M
(2003). Is ophthalmology evidence based? A clinical audit of the emergency unit of a regional eye hospital. Br J Ophthalmol
87: 385-390
[Abstract][Full Text]
Sellebjerg, F, Jensen, C V, Larsson, H B., Frederiksen, J L
(2003). Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Mult Scler
9: 102-107
[Abstract]
Khubchandani, R., Rane, T., Agarwal, P., Nabi, F., Patel, P., Shetty, A. K.
(2002). Bilateral Neuroretinitis Associated With Mumps. Arch Neurol
59: 1633-1636
[Abstract][Full Text]
Schapiro, R. T.
(2002). Pharmacologic Options for the Management of Multiple Sclerosis Symptoms. Neurorehabil Neural Repair
16: 223-231
[Abstract]
Wall, M., Neahring, R. K., Woodward, K. R.
(2002). Sensitivity and Specificity of Frequency Doubling Perimetry in Neuro-ophthalmic Disorders: A Comparison with Conventional Automated Perimetry. IOVS
43: 1277-1283
[Abstract][Full Text]
Kupersmith, M. J., Alban, T., Zeiffer, B., Lefton, D.
(2002). Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain
125: 812-822
[Abstract][Full Text]
Ghosh, A, Kelly, S P, Mathews, J, Cooper, P N, Macdermott, N
(2002). Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England. J. Neurol. Neurosurg. Psychiatry
72: 119-121
[Abstract][Full Text]
Defresne, P, Meyer, L, Tardieu, M, Scalais, E, Nuttin, C, De Bont, B, Loftus, G, Landrieu, P, Kadhim, H, Sebire, G
(2001). Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J. Neurol. Neurosurg. Psychiatry
71: 272-274
[Abstract][Full Text]
Leussink, V. I., Jung, S., Merschdorf, U., Toyka, K. V., Gold, R.
(2001). High-Dose Methylprednisolone Therapy in Multiple Sclerosis Induces Apoptosis in Peripheral Blood Leukocytes. Arch Neurol
58: 91-97
[Abstract][Full Text]
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., Weinshenker, B. G.
(2000). Multiple Sclerosis. NEJM
343: 938-952
[Full Text]
Miller, D. M, Weinstock-Guttman, B., Bethoux, F., Lee, J.-C., Beck, G., Block, V., Durelli, L., LaMantia, L., Barnes, D., Sellebjerg, F., Rudick, R. A
(2000). A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler
6: 267-273
[Abstract]
Schmidt, J., Gold, R., Schonrock, L., Zettl, U. K., Hartung, H.-P., Toyka, K. V.
(2000). T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain
123: 1431-1441
[Abstract][Full Text]
Kaufman, D. I., Trobe, J. D., Eggenberger, E. R., Whitaker, J. N.
(2000). Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology
54: 2039-2044
[Full Text]
Balcer, L. J, Baier, M. L, Pelak, V. S, Fox, R. J, Shuwairi, S., Galetta, S. L, Cutter, G. R, Maguire, M. G
(2000). New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler
6: 163-171
[Abstract]
Cole, S. R., Beck, R. W., Moke, P. S., Gal, R. L., Long, D. T.
(2000). The National Eye Institute Visual Function Questionnaire: Experience of the ONTT. IOVS
41: 1017-1021
[Abstract][Full Text]
Henson, D. B., Chaudry, S., Artes, P. H., Faragher, E. B., Ansons, A.
(2000). Response Variability in the Visual Field: Comparison of Optic Neuritis, Glaucoma, Ocular Hypertension, and Normal Eyes. IOVS
41: 417-421
[Abstract][Full Text]
Karussis, D., Weiner, H. L, Abramsky, O.
(1999). Multiple sclerosis vs Lyme disease: A case presentation to a discussant and a review of the literature. Mult Scler
5: 395-402
Metz, L. M., Sabuda, D., Hilsden, R. J., Enns, R., Meddings, J. B.
(1999). Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology
53: 2093-2093
[Abstract][Full Text]
Guy, J., Qi, X., Wang, H., Hauswirth, W. W.
(1999). Adenoviral Gene Therapy With Catalase Suppresses Experimental Optic Neuritis. Arch Ophthalmol
117: 1533-1539
[Abstract][Full Text]
McDonald, W I
(1999). Physicians, subsequence and consequence. J. Neurol. Neurosurg. Psychiatry
67: 282-289
[Full Text]
Tsubota, K., Satake, Y., Kaido, M., Shinozaki, N., Shimmura, S., Bissen-Miyajima, H., Shimazaki, J.
(1999). Treatment of Severe Ocular-Surface Disorders with Corneal Epithelial Stem-Cell Transplantation. NEJM
340: 1697-1703
[Abstract][Full Text]
Sellebjerg, F., Nielsen, H. S., Frederiksen, J. L., Olesen, J.
(1999). A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology
52: 1479-1479
[Abstract][Full Text]
Tselis, A. C., Lisak, R. P.
(1999). Multiple Sclerosis: Therapeutic Update. Arch Neurol
56: 277-280
[Full Text]
Guy, J., Qi, X., Hauswirth, W. W.
(1998). Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA
95: 13847-13852
[Abstract][Full Text]
MILLER, D H
(1998). Corticosteroids and multiple sclerosis. J. Neurol. Neurosurg. Psychiatry
65: 290-290
[Full Text]
Smith, D. R., Weiner, H. L.
(1997). Immunologic Aspects of Neurologic and Neuromuscular Diseases. JAMA
278: 1956-1961
[Abstract]
The Optic Neuritis Study Group,
(1997). Visual Function 5 Years After Optic Neuritis: Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol
115: 1545-1552
[Abstract]
Rudick, R. A., Cohen, J. A., Weinstock-Guttman, B., Kinkel, R. P., Ransohoff, R. M.
(1997). Management of Multiple Sclerosis. NEJM
337: 1604-1611
[Full Text]
Lucchinetti, C., Noseworthy, J., Rodriguez, M.
(1997). Promotion of endogeneous remyelination in Multiple Sclerosis. Mult Scler
3: 71-75
[Abstract]
Sébire, G., Hollenberg, H., Meyer, L., Huault, G., Landrieu, P., Tardieu, M.
(1997). High dose methylprednisolone in severe acute transverse myelopathy. Arch. Dis. Child.
76: 167-168
[Abstract][Full Text]
Rosenbaum, J. T, Simpson, J., Neuwelt, C M.
(1997). Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol
81: 130-132
[Abstract][Full Text]
Kalman, B., Rodriguez-Valdez, J. L., Bosch, U., Lublin, F. D
(1997). Screening for Leber's hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis. Mult Scler
2: 279-282
[Abstract]
Kappos, L.
(1996). Combinations of drugs. Mult Scler
1: 400-403
[Abstract]
Vollmer, T. L.
(1996). Multiple Sclerosis: New Approaches to Immunotherapy. Neuroscientist
2: 127-136
[Abstract]
Fendrick, A. M., Goodman, C. S., Trobe, J. D.
(1995). The Effectiveness Initiative: II: The Spectrum of Effectiveness Research. Arch Ophthalmol
113: 862-865
[Abstract]
Levin, L. A.
(1995). Ophthalmology. JAMA
273: 1703-1705
[Abstract]
Trobe, J. D., Fendrick, A. M.
(1995). The Effectiveness Initiative: I. Medical Practice Guidelines. Arch Ophthalmol
113: 715-717
[Abstract]
Beck, R. W., Optic Neuritis Study Group,
(1995). The Optic Neuritis Treatment Trial: Three-Year Follow-up Results. Arch Ophthalmol
113: 136-137
[Abstract]
Keltner, J. L., Johnson, C. A., Spurr, J. O., Beck, R. W., Optic Neuritis Study Group,
(1994). Visual Field Profile of Optic Neuritis: One-Year Follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol
112: 946-953
[Abstract]
Olek, M. J., Khan, O. A., Hart, R. G., Beck, R. W.
(1994). Corticosteroids, Optic Neuritis, and Multiple Sclerosis. NEJM
330: 1238-1239
[Full Text]
Wilson, W. B.
(1994). How Much Should We Editorialize?. Arch Ophthalmol
112: 298-299
[Abstract]
Beck, R. W., Optic Neuritis Study Group,
(1994). How Much Should We Editorialize?-Reply. Arch Ophthalmol
112: 299-299
[Abstract]
Seddon, J. M., Hennekens, C. H.
(1994). Vitamins, Minerals, and Macular Degeneration: Promising but Unproven Hypotheses. Arch Ophthalmol
112: 176-179
[Abstract]
Miller, A., Bourdette, D., Ritvo, P., Stuart, W., Vollmer, T.
(1994). The Neurologist's Perspective: What Do We Know and Where Do We Go?. Neurorehabil Neural Repair
8: 105-111
[Abstract]
Trobe, J. D.
(1994). High-Dose Corticosteroid Regimen Retards Development of Multiple Sclerosis in Optic Neuritis Treatment Trial. Arch Ophthalmol
112: 35-36
[Abstract]
Beck, R. W., Cleary, P. A., Trobe, J. D., Kaufman, D. I., Kupersmith, M. J., Paty, D. W., Brown, C. H., The Optic Neuritis Study Group,
(1993). The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis. NEJM
329: 1764-1769
[Abstract][Full Text]
Silberberg, D. H.
(1993). Corticosteroids and Optic Neuritis. NEJM
329: 1808-1810
[Full Text]
Beck, R. W., Arrington, J., Murtagh, F. R., Cleary, P. A., Kaufman, D. I., Optic Neuritis Study Group,
(1993). Brain Magnetic Resonance Imaging in Acute Optic Neuritis: Experience of the Optic Neuritis Study Group. Arch Neurol
50: 841-846
[Abstract]
Eddy, D. M.
(1993). Three Battles to Watch in the 1990s. JAMA
270: 520-526
[Abstract]
Joynt, R. J.
(1993). Neurology. JAMA
270: 228-230
[Abstract]
Beck, R. W., Cleary, P. A., Optic Neuritis Study Group,
(1993). Optic Neuritis Treatment Trial: One-Year Follow-up Results. Arch Ophthalmol
111: 773-775
[Abstract]
Chrousos, G. A., Kattah, J. C., Beck, R. W., Cleary, P. A., the Optic Neuritis Study Group, , Beck, R., Cleary, P., Keltner, J., Brodsky, M., McCrary, J. III, Katz, B., Buckley, E., Guy, J., Chrousos, G., Goodwin, J., Corbett, J., Saviano, P., Miller, N., Trobe, J., Kaufman, D., Kupers-mith, M., Shults, W., Smith, C.
(1993). Side Effects of Glucocorticoid Treatment: Experience of the Optic Neuritis Treatment Trial. JAMA
269: 2110-2112
[Abstract]
Beck, R. W., Cleary, P. A., Optic Neuritis Study Group,
(1993). Recovery From Severe Visual Loss in Optic Neuritis. Arch Ophthalmol
111: 300-300
[Abstract]
Keltner, J. L., Johnson, C. A., Spurr, J. O., Beck, R. W., Optic Neuritis Study Group,
(1993). Baseline Visual Field Profile of Optic Neuritis: The Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol
111: 231-234
[Abstract]
O'Brien, T. P., Goldberg, M. F.
(1992). Ophthalmology. JAMA
268: 393-395
[Abstract]
Beck, R. W., Optic Neuritis Study Group,
(1992). The Optic Neuritis Treatment Trial: Implications for Clinical Practice. Arch Ophthalmol
110: 331-332
(1992). IV STEROIDS MAY RESTORE VISION AFTER OPTIC NEURITIS. JWatch General
1992: 2-2
[Full Text]
